Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424471 | 1.00 | TDP1 (0.55) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL29673261 | 1.00 | TDP1 (0.55) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL697038 | 1.00 | TDP1 (0.55) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL8461991 | 0.98 | TDP1 (0.53) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL9529895 | 0.98 | TDP1 (0.53) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL29733565 | 0.93 | TDP1 (0.48) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL516874 | 0.93 | TDP1 (0.48) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL923829 | 0.93 | TDP1 (0.48) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| Water SCHEMBL4813848 | 0.91 | TDP1 (0.47) | TDP1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL6654554 | 0.83 | TDP1 (0.70) | TDP1ALDH1A1LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208903-A1 | ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE | Lophora ApS (DK) | 2024-06-27 | — | — | US | claimed |
| WO-2024130425-A1 | METHODS OF MAKING 2-AMINO-L-(3-HYDROXY-2,6-DIMETHYLPHENYL)-5,6- DIMETHYL-LH-PYRROLO-[2,3-B]PYRIDINE-3-CARBOXAMIDE, A MYTL INHIBITOR | REPARE THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | claimed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-3858816-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2021-08-04 | — | — | EP | claimed |
| US-10759776-B2 | Synthesis and resolution of nicotine | NJOY, LLC (US) | 2020-09-01 | — | — | US | claimed |
| WO-2020067683-A1 | NOVEL PROCESS FOR THE PREPARATION OF (+)-CIBENZOLINE SUCCINATE | CELLTRION INC. (KR) | 2020-04-02 | — | — | WO | claimed |
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | AMOREPACIFIC CORPORATION (KR) | 2019-11-19 | — | — | US | claimed |
| US-20190263777-A1 | SYNTHESIS AND RESOLUTION OF NICOTINE | NJOY, LLC (US) | 2019-08-29 | — | — | US | claimed |
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-08-13 | — | — | US | claimed |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2017-11-30 | — | — | US | claimed |
| US-9809567-B2 | Synthesis and resolution of nicotine | NJOY, LLC (US) | 2017-11-07 | — | — | US | claimed |
| EP-3162793-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | Amorepacific Corporation (KR) | 2017-05-03 | — | — | EP | claimed |
| US-20170066735-A1 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | ALPHORA RESEARCH INC. (CA) | 2017-03-09 | — | — | US | claimed |
| US-20160326134-A1 | SYNTHESIS AND RESOLUTION OF NICOTINE | NJOY, INC. (US) | 2016-11-10 | — | — | US | claimed |
| EP-2397461-A1 | Method for the manufacture of escitalopram | H. Lundbeck A/S (DK) | 2011-12-21 | — | — | EP | claimed |
| US-8022232-B2 | Method for manufacture of escitalopram | H. LUNDBECK A/S (DK) | 2011-09-20 | — | — | US | claimed |
| EP-2061753-B1 | METHOD FOR MANUFACTURE OF ESCITALOPRAM | LUNDBECK & CO AS H (DK) | 2011-08-03 | — | — | EP | claimed |
| US-20090069582-A1 | METHOD FOR MANUFACTURE OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2009-03-12 | — | — | US | claimed |
| US-6462229-B1 | IT HAS BEEN FOUND THAT (.+-.)-.ALPHA.-DIFLUOROMETHYLORNITHINE CAN BE CLEAVED USING THE COMMERCIALLY OBTAINABLE (-)-O,O'-DI-P-TOLUOYL-L-TARTARIC ACID | LONZA LTD. (CH) | 2002-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208903-A1 | ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE | CYP2D6, CYP3A5, CYP2B6 | TDP1 3683/4885ADRB2 799/4885ADRB1 1199/4885 |
| US-20170066735-A1 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | ERLIN1, ERLIN2, MAN1B1 | TDP1 2019/4885ADRB2 2597/4885ADRB1 1576/4885 |
| US-10479763-B2 | Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives | DHCR24, SRR, ACMSD | TDP1 2080/4885ADRB2 1629/4885ADRB1 1561/4885 |
| US-20090069582-A1 | METHOD FOR MANUFACTURE OF ESCITALOPRAM | HTR1A, HTR4, TPH1 | TDP1 70/4885ADRB2 234/4885ADRB1 58/4885 |
| US-20190263777-A1 | SYNTHESIS AND RESOLUTION OF NICOTINE | TMT1A, TST, NAPRT | TDP1 176/4885ADRB2 3199/4885ADRB1 2694/4885 |
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | C1S, FURIN, C5 | TDP1 4170/4885ADRB2 456/4885ADRB1 312/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | TDP1 1304/4885ADRB2 3554/4885ADRB1 3665/4885 |
| US-10759776-B2 | Synthesis and resolution of nicotine | TMT1A, TST, NAPRT | TDP1 176/4885ADRB2 3199/4885ADRB1 2694/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | TDP1 4567/4885ADRB2 1861/4885ADRB1 1485/4885 |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | DHCR24, SRR, ACMSD | TDP1 2080/4885ADRB2 1629/4885ADRB1 1561/4885 |
| US-20160326134-A1 | SYNTHESIS AND RESOLUTION OF NICOTINE | TMT1A, TST, NAPRT | TDP1 176/4885ADRB2 3199/4885ADRB1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.